SCHEMBL1496879

SCHEMBL1496879

CC(C)NC(=O)N(CCN1CCN(C)CC1)Cc1ccc(C(=O)Nc2cscc2NC(=O)OC(C)(C)C)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.36
FLT3 P36888 1/20 0.36
MCHR1 Q99705 3/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ABL1 P00519 1/20 0.35
SRC P12931 1/20 0.35
TRPA1 O75762 1/20 0.35
ATM Q13315 1/20 0.34
MAPK14 Q16539 2/20 0.34
PDCD1 Q15116 4/20 0.34
CD274 Q9NZQ7 4/20 0.34
ELANE P08246 1/20 0.33
ROCK2 O75116 2/20 0.33
ROCK1 Q13464 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496859 0.95 AVPR1A (0.38) CSF1RFLT3MCHR1HRH3ABL1
SCHEMBL3233734 0.93 MCHR1 (0.39) CSF1RFLT3MCHR1HRH3ABL1
SCHEMBL8001252 0.89 CSF1R (0.38) CSF1RFLT3MCHR1ABL1SRC
SCHEMBL1496870 0.89 AVPR1A (0.37) CSF1RFLT3ABL1SRCMEN1
SCHEMBL1496831 0.89 KDM4E (0.38) CSF1RFLT3MCHR1HRH3ABL1
SCHEMBL3233856 0.89 AVPR1A (0.42) MCHR1ABL1SRCPDCD1CD274
SCHEMBL1496873 0.88 USP2 (0.44) HRH3ATMCD274ROCK2MEN1
SCHEMBL1497074 0.88 USP2 (0.42) HRH3ATMCD274ROCK2MEN1
SCHEMBL1496943 0.86 KCNH2 (0.38) CSF1RFLT3MCHR1HRH3MAPK14
SCHEMBL1497091 0.86 TRPA1 (0.38) MCHR1HRH3TRPA1PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 CSF1R 2464/4885FLT3 1337/4885MCHR1 137/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 CSF1R 1291/4885FLT3 768/4885MCHR1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.